Key Updates
Since the July 17 report at £4,673, BATS.L has retraced 2.05% to £4,577. The decline follows a New York Times report dated July 16 detailing a U.S. federal and local criminal investigation into former NYC Sheriff Anthony M. Miranda and his possible involvement with BAT and its subsidiaries Reynolds American and R.J. Reynolds Tobacco Company. Prosecutors issued subpoenas seeking records related to the tobacco firms and communications with Mr. Miranda and his family, examining potential federal program fraud, bribery, wire fraud, and money laundering in connection with Operation Padlock to Protect.
Current Trend
YTD performance remains positive at +8.61%, with the 6-month return at +6.12%. The near-term picture is mixed: the 1-day change is -0.82%, the 5-day change is +0.93%, and the 1-month change is -0.17%. Since the June 29 restructuring announcement, the share price has exhibited volatility—dropping to £4,478 by July 9, rebounding to £4,673 by July 17, and now pulling back to £4,577. This establishes a recent trading range with support near the July 9 low of approximately £4,478 and resistance near the July 17 high of £4,673.
Investment Thesis
The core thesis rests on BAT's transition from traditional cigarettes to smoke-free alternatives and structural cost reduction. The company is targeting £600 million in annual savings by 2028 through a 19% workforce reduction (9,000 roles) and Accenture outsourcing, while reallocating resources to digital and AI-enabled operations. Diversification into vapes (Vuse) and nicotine pouches (Velo) continues, with revenue guidance for smoking alternatives raised despite steeper-than-expected cigarette volume declines. However, the thesis is now tempered by emerging U.S. legal risk and intensifying competitive pressure following the FDA's authorization of Philip Morris International's Zyn pouches as lower-risk alternatives.
Thesis Status
The operational turnaround thesis remains intact but the risk profile has deteriorated. The July 16 investigative report introduces material regulatory and reputational risk in BAT's U.S. operations, which could strain management bandwidth and potentially lead to financial penalties. This offsets some of the positive momentum from the June 29 restructuring announcement. The share price action—failure to hold the £4,673 level—suggests the market is digesting this new overhang rather than pricing in further operational gains.
Key Drivers
- U.S. Criminal Investigation: Federal and local authorities are investigating former NYC Sheriff Miranda and his ties to BAT/Reynolds American, with prosecutors examining potential bribery, wire fraud, and money laundering linked to Operation Padlock to Protect. BAT reported over $34 billion in worldwide revenue in 2025 and has been lobbying against menthol bans and unauthorized e-cigarette sales. Source: The New York Times
- Workforce Restructuring: BAT is cutting 9,000 jobs (19% of its 47,000-person workforce), including 5,500 direct cuts and 3,500 outsourced roles, to deliver £600 million in annual savings by 2028. The U.S. operations are excluded. Source: BBC Source: Financial Times
- Competitive FDA Authorization: The FDA approved Philip Morris International to market 20 Zyn variants as lower-risk than cigarettes, benefiting PMI and competitors including BAT and Altria by validating the oral nicotine pouch category. Source: Financial Times
- Smoke-Free Transition: BAT raised guidance for revenue growth from smoking alternatives (vapes and nicotine pouches) even as traditional cigarette volumes decline faster than expected. Source: Morningstar
Technical Analysis
The current price of £4,577 sits between the recent support level near £4,478 (July 9 low) and resistance at £4,673 (July 17 high). The -2.05% move since the last report breaks the prior recovery rally and suggests near-term consolidation within this range. A sustained break below £4,478 would signal further downside risk, while a move above £4,673 is needed to re-establish bullish momentum. The 5-day performance (+0.93%) indicates some intraweek stabilization, though the 1-day decline (-0.82%) shows ongoing selling pressure.
Bull Case
- Structural cost reduction: The 9,000-role restructuring (19% of workforce) targets £600 million in annual savings by 2028, excluding the U.S., materially improving the cost base and operational agility. Source: BBC
- Smoke-free growth trajectory: BAT raised revenue guidance for smoking alternatives such as Vuse and Velo despite accelerating cigarette volume declines, indicating successful portfolio pivot execution. Source: Morningstar
- Category validation from FDA: The FDA's authorization of Philip Morris's Zyn pouches as lower-risk alternatives reflects a positive regulatory stance toward oral nicotine pouches, which benefits BAT's competing Velo brand and the broader smoke-free ecosystem. Source: Financial Times
- Technology and AI integration: The Accenture partnership and shift toward digital, AI-enabled operations are designed to streamline supply-network operations and global service hubs, supporting long-term margin expansion. Source: The Guardian
- YTD outperformance: Shares remain up 8.61% year-to-date and 6.12% over six months, demonstrating resilient investor confidence in the turnaround narrative despite recent volatility. Source: The Guardian
Bear Case
- U.S. criminal investigation overhang: Federal and local authorities are actively investigating BAT's Reynolds American and R.J. Reynolds subsidiaries for potential federal program fraud, bribery, wire fraud, and money laundering tied to a former NYC sheriff, creating material regulatory and reputational risk. Source: The New York Times
- Accelerating cigarette decline: BAT faces steeper-than-expected declines in traditional cigarette volumes this year, pressuring top-line stability and cash flows from the core business segment as the smoke-free transition is not yet large enough to fully offset losses. Source: Morningstar
- Execution risk on restructuring: The scale of the 9,000-job reduction—5,500 direct cuts and 3,500 outsourced roles by year-end—carries significant operational disruption risk, potential loss of institutional knowledge, and uncertainty around achieving the full £600 million savings target by 2028. Source: BBC
- Competitive disadvantage in pouches: Philip Morris International received FDA authorization to market 20 Zyn variants with explicit reduced-risk claims, giving PMI a first-mover regulatory advantage over BAT's Velo in the U.S. oral nicotine pouch market. Source: Financial Times
- Near-term technical weakness: The failure to hold the £4,673 recovery high and subsequent -2.05% retracement to £4,577 indicates